Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

Stopped The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups.

Conditions

• Crohn's Disease

Interventions

• BIOLOGICAL: Brodalumab

Sponsor

Amgen